Clinical Research Experience:

• Phase III, Inoperable Gastric Cancer, Sub Investigator, SVIMS/2011, 
• Completed 20 Case Studies at time of M.D & D.M in NIMS & SVIMS 
• A Prospective, multicenter, randomised, double blinded, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitnib in combination with Folfiri 3 versus placebo in combination with Folfiri 3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer
• A prospective multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masatinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

• Clinico-pathological significance of HER 2 expression in gastric cancer: A retrospective study in Indian  population- JCO 2013, ASCO Vol 31, No 15-Supplymentay May 20, 2013 
• Letter to editor South Asian J Cancer 2013; 2: 192 
• Study of quality of life in brain tumor patients treated with three-dimensional conformal radiotherapy- JCO, 2010 ASCO Annual Meeting Proceedings( Post- Meeting Edition) Vol 28. No 15_ suppl ( May 20 supplement), 201: 2091